Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 194, n. 1, p. 25, doi. 10.1007/s10549-022-06615-2
- By:
- Publication type:
- Article